Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
synthetic cannabinoid
|
| gptkbp:actsOn |
CB1 receptor agonist
CB2 receptor agonist |
| gptkbp:CASNumber |
335161-24-5
|
| gptkbp:category |
gptkb:naphthoylindole
fluorinated compound indole-based cannabinoid |
| gptkbp:chemicalFormula |
C24H22N2O
|
| gptkbp:designer_drug |
yes
|
| gptkbp:discoveredBy |
Alexandros Makriyannis
|
| gptkbp:firstReported |
2011
|
| https://www.w3.org/2000/01/rdf-schema#label |
AM-2201
|
| gptkbp:IUPACName |
1-(5-fluoropentyl)-3-(1-naphthoyl)indole
|
| gptkbp:legal_status_in_Germany |
Anlage II controlled substance
|
| gptkbp:legal_status_in_UK |
Class B drug
|
| gptkbp:legalStatus |
Schedule I controlled substance
|
| gptkbp:molecularWeight |
370.45 g/mol
|
| gptkbp:relatedTo |
gptkb:JWH-018
UR-144 |
| gptkbp:routeOfAdministration |
oral
inhalation |
| gptkbp:sideEffect |
vomiting
anxiety hypertension paranoia seizures tachycardia hallucinations agitation |
| gptkbp:toxicity |
high
|
| gptkbp:used_in |
synthetic cannabis products
|
| gptkbp:bfsParent |
gptkb:JWH-018
gptkb:PB-18 |
| gptkbp:bfsLayer |
7
|